PASSIVE IMMUNIZATION: TREATMENT OF RABIES VIRUS INFECTION WITH HUMANMONOCLONAL ANTIBODIES NIH GUIDE, Volume 24, Number 4, February 3, 1995 RFP AVAILABLE: NIH-NIDR-2-95-6R P.T. 34 Keywords: Viral Studies (Virology) Monoclonal Antibodies National Institute of Dental Research The National Institute of Dental Research (NIDR) has a requirement for the generation of rabies virus neutralizing human monoclonal antibody (mAbs), preferentially of the high affinity IgG isotype, so that a "cocktail" of several neutralizing human mAbs can be prepared against multiple antigenic sites on the viral glycoprotein (GP) and ribonucleoprotein (RNP) complex. The specific objectives of the project are: (1) to generate at least 15 high affinity virus- neutralizing human mAbs against various antigenic determinants on rabies virus using human hybridoma technology, and (2) to show that these mAbs protect animals against lethal rabies challenge. Offerors must have access to blood from healthy donors immunized with rabies vaccine and must demonstrate previous successful establishment of mAbs. INQUIRIES Request for Proposals (RFP) NIH-NIDR-2-95-6R will be available approximately February 17, 1995, with proposals due on or about March 30, 1995. Requests for the RFP may be addressed to: Ms. Marion L. Blevins Contract Management Section National Institute of Dental Research Natcher Building, Room 4AN-44D Bethesda, MD 20892
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |